combination drug therapy

Summary

Summary: Therapy with two or more separate preparations given for a combined effect.

Top Publications

  1. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
  3. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
  4. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
  5. doi Effects of intensive glucose lowering in type 2 diabetes
    Hertzel C Gerstein
    N Engl J Med 358:2545-59. 2008
  6. doi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
  7. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
  8. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
  9. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
  10. ncbi Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetologia 50:1148-55. 2007

Detail Information

Publications282 found, 100 shown here

  1. ncbi Telmisartan, ramipril, or both in patients at high risk for vascular events
    Salim Yusuf
    Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada
    N Engl J Med 358:1547-59. 2008
    ..We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes...
  2. ncbi Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    Michael W Fried
    University of North Carolina, Chapel Hill 27599, USA
    N Engl J Med 347:975-82. 2002
    ..We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C...
  3. ncbi Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    Peter M A Calverley
    University Hospital Aintree, Liverpool, United Kingdom
    N Engl J Med 356:775-89. 2007
    ..Long-acting beta-agonists and inhaled corticosteroids are used to treat chronic obstructive pulmonary disease (COPD), but their effect on survival is unknown...
  4. ncbi Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  5. doi Effects of intensive glucose lowering in type 2 diabetes
    Hertzel C Gerstein
    N Engl J Med 358:2545-59. 2008
    ....
  6. doi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
    ..In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain...
  7. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
    ..The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain...
  8. ncbi Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose
    Stephanos J Hadziyannis
    Department of Medicine and Hepatology, Henry Dunant Hospital, Athens, Greece
    Ann Intern Med 140:346-55. 2004
    ..Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional interferon and ribavirin in patients with chronic hepatitis C...
  9. ncbi In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem)
    Christin Sisowath
    Malaria Research Laboratory, Unit of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
    J Infect Dis 191:1014-7. 2005
    ..This points to 86N as a potential marker of lumefantrine resistance in vivo, while suggesting that Coartem is not robust enough to avoid selection of resistance-associated mutations in some malarial settings...
  10. ncbi Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
    V Fonseca
    Endocrinology Department, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
    Diabetologia 50:1148-55. 2007
    ..This study assessed the efficacy and tolerability of vildagliptin added to insulin therapy in patients with type 2 diabetes...
  11. ncbi Moderate effect of artemisinin-based combination therapy on transmission of Plasmodium falciparum
    J Teun Bousema
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    J Infect Dis 193:1151-9. 2006
    ....
  12. ncbi Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD
    J A Van Noord
    Dept of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Eur Respir J 26:214-22. 2005
    ..i.d. A combination of both drugs q.d. was most effective and provided an additive effect throughout the 24-h dosing interval...
  13. ncbi Viral hepatitis B
    Ching Lung Lai
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, People s Republic of China
    Lancet 362:2089-94. 2003
    ..Lamivudine, and presumably other nucleoside analogues, can reverse cirrhosis of the liver...
  14. ncbi Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
    A M Shapiro
    Surgical Medical Research Institute and the Department of Surgery, University of Alberta, Edmonton, Canada
    N Engl J Med 343:230-8. 2000
    ..Registry data on patients with type 1 diabetes mellitus who undergo pancreatic islet transplantation indicate that only 8 percent are free of the need for insulin therapy at one year...
  15. ncbi Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD
    Jan A van Noord
    Department of Respiratory Diseases, Atrium Medisch Centrum, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands
    Chest 129:509-17. 2006
    ..The combination of short-acting beta(2)-agonists and anticholinergics in the treatment of COPD has been well documented, but data on combination of long-acting agents are lacking...
  16. ncbi Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number
    Ric N Price
    Department of Cellular and Molecular Medicine Infectious Diseases, St George s Hospital Medical School, London, UK
    Lancet 364:438-47. 2004
    ..A combination of artesunate with mefloquine now cures more than 95% of acute infections. For both treatment regimens, the underlying mechanisms of resistance are not known...
  17. ncbi Irbesartan in patients with heart failure and preserved ejection fraction
    Barry M Massie
    University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
    N Engl J Med 359:2456-67. 2008
    ..Therefore, we studied the effects of irbesartan in patients with this syndrome...
  18. ncbi Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda
    Carole Fogg
    Epicentre, Paris, France
    Am J Trop Med Hyg 71:525-30. 2004
    ..The high adherence to artemether-lumefantrine found in our study suggest that this drug is likely to be very effective in Mbarara provided that patients receive clear dosage explanations...
  19. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
    ..The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown...
  20. ncbi Mass treatment to eliminate filariasis in Papua New Guinea
    Moses J Bockarie
    Papua New Guinea Institute of Medical Research, Goroka, Madang, Papua New Guinea
    N Engl J Med 347:1841-8. 2002
    ..The goal is to reduce the reservoir of microfilariae in the blood to a level that is insufficient to maintain transmission by the mosquito vector...
  21. ncbi Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
    Peter Ferenci
    Medical University of Vienna, Vienna, Austria
    J Hepatol 43:425-33. 2005
    ..Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy...
  22. ncbi Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group
    D E Niewoehner
    Veterans Affairs Medical Center in Minneapolis, MN 55417, USA
    N Engl J Med 340:1941-7. 1999
    ..The primary end point was treatment failure, defined as death from any cause or the need for intubation and mechanical ventilation, readmission to the hospital for COPD, or intensification of drug therapy...
  23. ncbi Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
    S G Deeks
    University of California, San Francisco, and San Francisco General Hospital, USA
    N Engl J Med 344:472-80. 2001
    ..In many patients with human immunodeficiency virus (HIV) infection, therapy with potent antiretroviral drugs does not result in complete suppression of HIV replication. The effect of cessation of therapy in these patients is unknown...
  24. ncbi The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  25. pmc Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials
    Lucy C Okell
    Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
    Malar J 7:125. 2008
    ..The size of this effect is estimated in symptomatic P. falciparum infections...
  26. ncbi The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
    Matthew C Riddle
    Oregon Health and Science University, Portland, Oregon 97201, USA
    Diabetes Care 26:3080-6. 2003
    ..To compare the abilities and associated hypoglycemia risks of insulin glargine and human NPH insulin added to oral therapy of type 2 diabetes to achieve 7% HbA(1c)...
  27. ncbi Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes
    Antonio Anzueto
    University of Texas Health Science Center at San Antonio, San Antonio, TX, 78230, USA
    COPD 6:320-9. 2009
    ..2%). FSC 250/50 is more effective than SAL at reducing the rate of moderate/severe exacerbations. These data confirm the beneficial effect of FSC on the management of COPD exacerbations and support the use of FSC in patients with COPD...
  28. ncbi Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Hepatology 38:645-52. 2003
    ..Patients who fail to achieve EVR will not clear virus even if an additional 9 months of therapy is received. Therapy can be confidently discontinued in those cases...
  29. ncbi Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
    Kenneth Jamerson
    Division of Cardiovascular Medicine, University of Michigan Health System, 24 Frank Lloyd Wright Dr, Lobby M, Ann Arbor, MI 48106, USA
    N Engl J Med 359:2417-28. 2008
    The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic...
  30. ncbi Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B
    Bjorn Dahlof
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Lancet 366:895-906. 2005
    ..Our aim, therefore, was to compare the effect on non-fatal myocardial infarction and fatal CHD of combinations of atenolol with a thiazide versus amlodipine with perindopril...
  31. pmc Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic
    Christian Dokomajilar
    Department of Medicine, University of California San Francisco, San Francisco General Hospital, Box 0811, San Francisco, CA 94143, USA
    Antimicrob Agents Chemother 50:1893-5. 2006
    ..All samples had a single pfmdr1 copy. Treatment with artemether-lumefantrine selects for polymorphisms that may alter antimalarial drug response...
  32. pmc Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, P O Box 46, Mae Sot, Tak 63110, Thailand
    Antimicrob Agents Chemother 50:2281-5. 2006
    ..This new regimen is well tolerated and results in an equivalent therapeutic response...
  33. ncbi Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
    Peter Calverley
    Department of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK
    Lancet 361:449-56. 2003
    ..We postulated that a combination of these treatments would be better than each component used alone...
  34. ncbi Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes
    Michael N Cook
    Department of Epidemiology, Merck Research Laboratories, Merck, BL 1 7, P O Box 4, West Point, PA 19486 0004, USA
    Diabetes Care 28:995-1000. 2005
    ..To describe the course and predictors of glycemic control among patients with type 2 diabetes after sulfonylureas (SUs) are added to metformin (MF)...
  35. pmc Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand
    J Tarning
    Department of Pharmacology, Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
    Antimicrob Agents Chemother 52:1052-61. 2008
    ..Our data lend further support to a simplified once-daily treatment regimen to improve treatment adherence and efficacy and indicate that weight-adjusted piperaquine doses in children may need to be higher than in adults...
  36. ncbi Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
    B G Brown
    Department of Medicine, University of Washington School of Medicine, Seattle 98195, USA
    N Engl J Med 345:1583-92. 2001
    ..CONCLUSIONS: Simvastatin plus niacin provides marked clinical and angiographically measurable benefits in patients with coronary disease and low HDL levels. The use of antioxidant vitamins in this setting must be questioned...
  37. ncbi Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial
    James Kennedy
    Acute Stroke Programme, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
    Lancet Neurol 6:961-9. 2007
    ..Patients with transient ischaemic attack (TIA) or minor stroke are at high immediate risk of stroke. The optimum early treatment options for these patients are not known...
  38. pmc Antimalarial drug resistance
    Nicholas J White
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    J Clin Invest 113:1084-92. 2004
    ..Artemisinin-derivative combinations are particularly effective, since they act rapidly and are well tolerated and highly effective. Widespread use of these drugs could roll back malaria...
  39. ncbi Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
    K Hermansen
    Aarhus University Hospital, Aarhus, Denmark
    Diabetes Obes Metab 9:733-45. 2007
    ..5% and <or=10.5%] while on glimepiride alone or in combination with metformin...
  40. ncbi Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
    Barry J Goldstein
    Division of Endocrinology, Diabetes, and Metabolic Diseases, Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Diabetes Care 30:1979-87. 2007
    ..To assess the efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes and inadequate glycemic control on diet and exercise...
  41. ncbi The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD
    Mario Cazzola
    Unit of Pneumology and Allergology, Department of Respiratory Medicine, A Cardarelli Hospital, Via del Parco Margherita 24, Naples 80121, Italy
    Pulm Pharmacol Ther 17:35-9. 2004
    ..Since tiotropium ensures prolonged bronchodilation, whereas formoterol adds fast onset and a greater peak effect, the two drugs appear complementary...
  42. ncbi Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
    Neil C Barnes
    Department of Respiratory Medicine, London Chest Hospital, London, UK
    Am J Respir Crit Care Med 173:736-43. 2006
    ..No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive pulmonary disease...
  43. pmc Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial
    Alastair D Hay
    Academic Unit of Primary Health Care, NIHR National School for Primary Care Research, Department of Community Based Medicine, University of Bristol, Bristol BS8 2AA
    BMJ 337:a1302. 2008
    ..To investigate whether paracetamol (acetaminophen) plus ibuprofen are superior to either drug alone for increasing time without fever and the relief of fever associated discomfort in febrile children managed at home...
  44. pmc A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp
    V Y Belizario
    Department of Parasitology, College of Public Health, University of the Philippines Manila, Ermita, Manila, Philippines
    Bull World Health Organ 81:35-42. 2003
    ....
  45. pmc Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis
    Mical Paul
    Rabin Medical Centre, Beilinson Campus, Infectious Diseases Unit and Department of Medicine E, Petah Tiqva 49100, Israel
    BMJ 326:1111. 2003
    ..To compare the effectiveness of beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy in the treatment of patients with fever and neutropenia...
  46. ncbi Autoimmune hepatitis
    Edward L Krawitt
    Department of Medicine, University of Vermont, Burlington, VT 05405 0068, USA
    N Engl J Med 354:54-66. 2006
  47. ncbi Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
    Ralph A DeFronzo
    Division of Diabetes, University of Texas Health Science Center, San Antonio, TX, USA
    Diabetes Care 28:1092-100. 2005
    ..This study evaluates the ability of the incretin mimetic exenatide (exendin-4) to improve glycemic control in patients with type 2 diabetes failing to achieve glycemic control with maximally effective metformin doses...
  48. ncbi Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection
    M Hojo
    Dept. of Gastroenterology, Juntendo University, School of Medicine, Tokyo, Japan
    Scand J Gastroenterol 36:690-700. 2001
    ..The strategy of adding two new antimicrobials to previous regimens was also effective in re-eradication therapy...
  49. pmc Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation
    Daniel J Tisch
    Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio 44106 7286, USA
    Am J Trop Med Hyg 78:289-93. 2008
    ..These data suggest that Bm14 antibody may be a sensitive test to monitor continuing transmission during and after mass drug administration aimed at eliminating transmission of lymphatic filariasis...
  50. ncbi A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study
    Peter H Katelaris
    Department of Gastroenterology, Concord Hospital, University of Sydney, West, Australia
    Gastroenterology 123:1763-9. 2002
    ..Direct comparisons of bismuth and proton pump inhibitor (PPI)-based triple and quadruple therapies for Helicobacter pylori eradication are lacking. To address this, a randomized study was conducted...
  51. ncbi Artemisinin-based combinations
    Elizabeth A Ashley
    Shoklo Malaria Research Unit, Mae Sot, Tak, Thailand
    Curr Opin Infect Dis 18:531-6. 2005
    ..Artemisinin-based combination treatments have been the mainstay of treatment for falciparum malaria in Southeast Asia for more than 10 years and are now increasingly recommended as first-line treatment throughout the rest of the world...
  52. ncbi Salmeterol plus theophylline combination therapy in the treatment of COPD
    R L ZuWallack
    Section of Pulmonary Medicine, St. Francis Hospital and Medical Center, Hartford, CT 06105, USA
    Chest 119:1661-70. 2001
    ..CONCLUSION: Patients with COPD may benefit from combination treatment with salmeterol plus theophylline, without a resulting increase in adverse events or other adverse sequelae...
  53. ncbi Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa
    Matthew Scarborough
    College of Medicine, Blantyre, Malawi
    N Engl J Med 357:2441-50. 2007
    ..Adjuvant therapy with corticosteroids reduces mortality among adults in the developed world, but it has not been adequately tested in developing countries or in the context of advanced human immunodeficiency virus (HIV) infection...
  54. pmc Differences in willingness to pay for artemisinin-based combinations or monotherapy: experiences from the United Republic of Tanzania
    Virginia Wiseman
    Department of Public Health and Policy, London School of Hygiene and Tropical Medicine, 50 Bedford Square, London WC1B 3DP, England
    Bull World Health Organ 83:845-52. 2005
    ..The reasons behind respondents' valuations and the effect of socioeconomic status on willingness to pay were explored...
  55. ncbi The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis
    Ishraga E A-Elbasit
    Malaria Research Centre, Department of Biochemistry, University of Khartoum, Khartoum, Sudan
    Trop Med Int Health 11:604-12. 2006
    ..To compare the efficacy of sulfadoxine-pyremethamine (SP)+chloroquine (CQ) combination treatment against falciparum malaria with SP treatment alone...
  56. ncbi Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome
    Timothy H Holtz
    Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Ann Intern Med 144:650-9. 2006
    ....
  57. pmc Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy
    Nagesh Kolishetti
    Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 107:17939-44. 2010
    ..therapeutic targets for a plethora of diseases, creating a need to develop robust technologies for combination drug therapy. In the present work, we describe a self-assembled polymeric nanoparticle (NP) platform to target and ..
  58. ncbi Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs
    M C J M Sturkenboom
    Department of Epidemiology and Biostatistics, Medical Informatics, Erasmus University, Rotterdam, The Netherlands
    Aliment Pharmacol Ther 18:1137-47. 2003
    ..The efficacy of proton pump inhibitors (PPIs) or histamine-2 receptor antagonists (H2RAs) prescribed as prophylaxis for NSAID-related upper gastrointestinal (UGI) toxicity is dependent upon patient adherence...
  59. pmc Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis
    Pablo San Gabriel
    Department of Pediatrics, Columbia University, New York, New York 10032, USA
    Antimicrob Agents Chemother 48:168-71. 2004
    ..To determine appropriate treatment for patients with CF, it is important to monitor the prevalence, antimicrobial susceptibility, and clinical impact of S. maltophilia in this patient population...
  60. ncbi Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
    Juan Berenguer
    Hospital Gregorio Maranon, Madrid, Spain
    Hepatology 50:407-13. 2009
    ..96 (95% confidence interval, 2.27; 10.85, P < 0.001) for patients with fibrosis grade of F3-F4 versus those with F0-F2.Because this was not a prospective study, selection and survival biases may influence estimates of effect...
  61. ncbi Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies
    Michael R Horsman
    Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
    Cancer Res 66:11520-39. 2006
    ..This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy...
  62. ncbi Topiramate as add-on treatment for patients with bipolar mania
    K N Chengappa
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, PA 15215 2593, USA
    Bipolar Disord 1:42-53. 1999
    ..Topiramate (Topamax), a new antiepileptic agent, is a candidate drug for bipolar disorder. We evaluated topiramate as adjunctive treatment for bipolar patients...
  63. ncbi Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
    Rury R Holman
    Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, University of Oxford, Headington, Oxford, United Kingdom
    N Engl J Med 357:1716-30. 2007
    ..Adding insulin to oral therapy in type 2 diabetes mellitus is customary when glycemic control is suboptimal, though evidence supporting specific insulin regimens is limited...
  64. ncbi Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial
    Steven R Steinhubl
    Division of Cardiology, University of North Carolina, CB 7075, 338 Burnett Womack Bldg, Chapel Hill, NC 27599, USA
    JAMA 288:2411-20. 2002
    ..Also, although current clinical data suggest a benefit for beginning therapy with a clopidogrel loading dose prior to PCI, the practical application of this therapy has not been prospectively studied...
  65. ncbi Combination antiretroviral therapy and the risk of myocardial infarction
    Nina Friis-Møller
    N Engl J Med 349:1993-2003. 2003
    ..It remains controversial whether exposure to combination antiretroviral treatment increases the risk of myocardial infarction...
  66. ncbi Treatment of human brucellosis with rifampin plus minocycline
    A Cascio
    AILMI Associazione Italiana per la Lotta contro le Malattie Infettive c o Scuola di Specializzazione in Malattie Infettive Università di Messina, Via Consolare Valeria n 1, 98125 Messina, Italy
    J Chemother 15:248-52. 2003
    ..A randomized prospective comparative study should be performed to confirm our encouraging results...
  67. ncbi Optimal medical therapy with or without PCI for stable coronary disease
    William E Boden
    Western New York Veterans Affairs Healthcare Network and Buffalo General Hospital SUNY, Buffalo, NY 14203, USA
    N Engl J Med 356:1503-16. 2007
    ....
  68. pmc In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals
    Seif A Shekalaghe
    Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
    Antimicrob Agents Chemother 54:1762-8. 2010
    ..PQ may cause moderate anemia when coadministered with artemisinins, and excluding individuals based on G6PD status alone may not be sufficient to prevent PQ-induced hemolysis...
  69. ncbi Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
    Lars Klareskog
    Rheumatology Unit, Department of Medicine, Karolinska Institute Karolinska Hospital, Stockholm 17176, Sweden
    Lancet 363:675-81. 2004
    ..We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis...
  70. ncbi Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
    Harry L A Janssen
    Department of Gastroenterology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
    Lancet 365:123-9. 2005
    ..Treatment of HBeAg-positive patients with chronic hepatitis B is not effective in most. A combination of immunomodulatory pegylated interferon alfa-2b and antiviral lamivudine might improve the rate of sustained response...
  71. ncbi Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study
    Bryan Williams
    Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
    Circulation 113:1213-25. 2006
    ....
  72. ncbi Tolerance is the key to understanding antimalarial drug resistance
    Ian M Hastings
    Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
    Trends Parasitol 22:71-7. 2006
    ..This intermediate stage between fully sensitive and fully resistant parasites has far-reaching implications for the evolution of drug-resistant malaria...
  73. pmc Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria
    Peter J Hotez
    Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington, District of Columbia, USA
    PLoS Med 3:e102. 2006
  74. ncbi Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol
    Gerard M London
    Hopital Manhes, Fleury Merogis, France
    J Am Coll Cardiol 43:92-9. 2004
    ....
  75. ncbi Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
    William J Burman
    Denver Public Health and the Department of Medicine, University of Colorado Health Sciences National Jewish Medical and Research Center, Denver, Colorado, USA
    Am J Respir Crit Care Med 174:331-8. 2006
    ..Moxifloxacin has promising preclinical activity against Mycobacterium tuberculosis, but has not been evaluated in multidrug treatment of tuberculosis in humans...
  76. ncbi The role of sulphonylureas in the management of type 2 diabetes mellitus
    Marc Rendell
    Creighton Diabetes Center, 601 North 30th Street, Omaha, NE 68131, USA
    Drugs 64:1339-58. 2004
    ..Sulphonylureas will continue to be used both primarily and as part of combined therapy for most patients with type 2 diabetes...
  77. ncbi A randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia
    B Janssens
    Medecins Sans Frontieres, Phnom Penh, Cambodia
    Trop Med Int Health 12:251-9. 2007
    ..To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia...
  78. pmc Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy
    Samuel Shillcutt
    Andean Health and Development Saludesa, Quito, Ecuador
    Bull World Health Organ 86:101-10. 2008
    ..To evaluate the relative cost-effectiveness in different sub-Saharan African settings of presumptive treatment, field-standard microscopy and rapid diagnostic tests (RDTs) to diagnose malaria...
  79. ncbi Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
    Richard J Saad
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Am J Gastroenterol 101:488-96. 2006
    ..Levofloxacin-based triple therapy has been suggested as an alternative salvage therapy to bismuth-based quadruple therapy for persistent Helicobacter pylori (H. pylori) infection...
  80. ncbi Intercontinental spread of pyrimethamine-resistant malaria
    Cally Roper
    London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
    Science 305:1124. 2004
    ..The resistance alleles carried by these migrants are now spreading across Africa at an alarming rate, signaling the end of affordable malaria treatment and presenting sub-Saharan Africa with a public health crisis...
  81. pmc Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
    M Marre
    Service d Endocrinologie Diabétologie Nutrition, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    Diabet Med 26:268-78. 2009
    ..To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) or rosiglitazone 4 mg/day (all n >or= 228) or placebo (n = 114) with glimepiride (2-4 mg/day) on glycaemic control, body weight and safety in Type 2 diabetes...
  82. ncbi Lead induced oxidative damage and its response to combined administration of alpha-lipoic acid and succimers in rats
    Manisha Pande
    Division of Pharmacology and Toxicology, Defence Research and Development Establishment, Jhansi Road, Gwalior, India
    Toxicology 177:187-96. 2002
    ..The results thus provide evidence of an encouraging role of LA when given in combination with a thiol chelator in the therapeutic intervention of lead poisoning, particularly in reducing the oxidative stress and brain lead concentration...
  83. ncbi Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials
    Matthew J Taylor
    Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK
    J Psychopharmacol 18:251-6. 2004
    ..It is currently unclear if this is the case both for people with normal folate levels, and for those with folate deficiency...
  84. pmc Influence of rapid malaria diagnostic tests on treatment and health outcome in fever patients, Zanzibar: a crossover validation study
    Mwinyi I Msellem
    Malaria Control Programme, Ministry of Health and Social Welfare, Zanzibar, Tanzania
    PLoS Med 6:e1000070. 2009
    ..Our objective was to study the influence of RDT-aided malaria diagnosis on drug prescriptions, health outcomes, and costs in primary health care settings...
  85. pmc Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis
    T Mimura
    Departments of Medicine, Surgery, and Pathology, St Mark s Hospital, London, UK
    Gut 53:108-14. 2004
    ..The aim of this study was to evaluate the effectiveness of a single daily high dose probiotic preparation (VSL#3) in maintaining antibiotic induced remission, and quality of life (QOL), for one year in such patients...
  86. ncbi Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C
    Yoshiaki Iwasaki
    Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
    Hepatology 43:54-63. 2006
    ..Thus, treatment schedule should be modified, or other therapeutic modalities should be considered for older patients with chronic hepatitis C...
  87. ncbi A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis
    Arun J Sanyal
    Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Comonwealth University Medical Center, Richmond, VA 23298 0711, USA
    Clin Gastroenterol Hepatol 2:1107-15. 2004
    ....
  88. ncbi Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices
    Shunmay Yeung
    Wellcome Trust Mahidol University Oxford Tropical Medicine Research Program, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Am J Trop Med Hyg 71:179-86. 2004
    ....
  89. ncbi Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease
    Kristen E Belmonte
    Respiratory and Inflammation Centre of Excellence in Drug Discovery, GlaxoSmithKline, King of Prussia, PA, USA
    Proc Am Thorac Soc 2:297-304; discussion 311-2. 2005
    ..Adequate concurrent blockade of M3 muscarinic receptors would be expected to counteract the enhanced acetylcholine release that would result from blockade of neuronal inhibitory M2 muscarinic receptors...
  90. ncbi Multicomponent therapeutics for networked systems
    Curtis T Keith
    CombinatoRx, Inc, 650 Albany Street, Boston, Massachusetts 02118, USA
    Nat Rev Drug Discov 4:71-8. 2005
    ..A systems perspective facilitates an understanding of the mechanism of action of such drug combinations...
  91. pmc IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    P Emery
    Leeds Teaching Hospitals Trust, University of Leeds, Leeds, UK
    Ann Rheum Dis 67:1516-23. 2008
    ..The phase III RADIATE study examined the efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody in patients with rheumatoid arthritis (RA) refractory to tumour necrosis factor (TNF) antagonist therapy...
  92. ncbi Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial
    Shawn D Aaron
    The Ottawa Health Research Institute and University of Ottawa, Ottawa, Ontario, Canada
    Ann Intern Med 146:545-55. 2007
    ..Treatment of moderate or severe chronic obstructive pulmonary disease (COPD) with combinations of inhaled corticosteroids, long-acting beta-agonists, and long-acting anticholinergic bronchodilators is common but unstudied...
  93. ncbi Antibiotic resistance in the intensive care unit
    M H Kollef
    Campus Box 8052, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA
    Ann Intern Med 134:298-314. 2001
    ..Careful, focused attention to this problem at the local ICU level, using a multidisciplinary approach, will have the greatest likelihood of limiting the development and dissemination of antibiotic-resistant infections...
  94. ncbi Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use
    F Javier Pérez-Victoria
    Instituto de Parasitologia y Biomedicina Lopez Neyra, Spanish Research Council C S I C, Technological Park of Health Sciences, Avda del Conocimiento s n, 18100 Armilla, Granada, Spain
    Drug Resist Updat 9:26-39. 2006
    ....
  95. ncbi Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study
    Peter H Jones
    Baylor College of Medicine, Houston, TX 77030, USA
    Atherosclerosis 204:208-15. 2009
    ..To evaluate a new formulation of fenofibric acid (ABT-335) co-administered with 2 doses of rosuvastatin in patients with mixed dyslipidemia...
  96. ncbi Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study
    B Ledergerber
    Division of Infectious Diseases and Hospital Epidemiology, University of Zurich, Switzerland
    Lancet 353:863-8. 1999
    ..The efficacy of highly active antiretroviral therapy (HAART) in suppression of HIV-1 is well documented. We investigated virological and clinical outcomes of HAART in routine practice...
  97. ncbi Reduced hospital stay and narcotic consumption, and improved mobilization with local and intraarticular infiltration after hip arthroplasty: a randomized clinical trial of an intraarticular technique versus epidural infusion in 80 patients
    Karen V Andersen
    Department of Orthopedic Surgery, Aarhus University Hospital, Aarhus, Denmark
    Acta Orthop 78:180-6. 2007
    ..We compared wound infiltration combined with intraarticular injection of local anesthetics for pain relief after total hip arthroplasty (THA) with the well-established practice of epidural infusion...
  98. ncbi Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study
    F Alvarez Guisasola
    Centro de Salud La Calzada II, Gijon, Spain
    Diabetes Obes Metab 10:8-15. 2008
    ....
  99. ncbi Postoperative analgesia in total hip arthroplasty: a randomized double-blinded, placebo-controlled study on peroperative and postoperative ropivacaine, ketorolac, and adrenaline wound infiltration
    Lasse Juel Andersen
    Department of Orthopaedic Surgery, Odense University Hospital, Middelfart, Denmark
    Acta Orthop 78:187-92. 2007
    ..Comfort and lack of pain are important for optimal mobilization after hip replacement. We investigated the efficacy of double wound infiltration...
  100. ncbi Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    Mauricio Tohen
    Lilly Research Laboratories, Indianapolis, Indiana 46285, USA
    Br J Psychiatry 184:337-45. 2004
    ..Aims To evaluate whether olanzapine plus either lithium or valproate reduces the rate of relapse, compared with lithium or valproate alone...
  101. ncbi A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial
    Carl J Pepine
    Division of Cardiovascular Medicine, Department of Medicine, University of Florida College of Medicine, Gainesville 32610, USA
    JAMA 290:2805-16. 2003
    ..Despite evidence of efficacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypertensive agents for coronary artery disease (CAD) have been discerned only from subgroup analyses in large trials...

Research Grants62

  1. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    ..We therefore anticipate rapid translation of the optimized promising pretargeted RIT into our clinical RIT HCT program for AML and MDS. ..
  2. Role of IGF-IR tyrosine kinase in NPM-ALK-expressing T-cell lymphoma
    Hesham M Amin; Fiscal Year: 2013
    ..Our long-term goal is to understand IGF-IR-dependent signaling in this aggressive lymphoma in order to devise novel therapeutic strategies. Tactics that antagonize IGF-IR could potentially provide a cure for NPM-ALK+ ALCL patients. ..
  3. Improved idiotype immunotherapy for lymphoma by RNA vaccine delivery
    ALISON ANNE MCCORMICK; Fiscal Year: 2010
    ..Unlike current therapies, custom vaccines are easily made, and may facilitate widespread adoption of individualized patient immunotherapy. ..
  4. In Vivo Imaging of bcl-2 Expression in Lymphoma
    Michael R Lewis; Fiscal Year: 2012
    ..5% of its victims are U.S. war veterans. The goal of the proposed research is central to the VHA mission of providing primary and specialized care to cancer patients who are veterans. ..
  5. 1H MRI based nanosensors for imaging tumor oxygenation
    Vikram D Kodibagkar; Fiscal Year: 2010
    ..Although we study tumors, the technique developed here has potential applications in a wide range of diseased states and can be applied to study basic physiology and oxygen consumption in tissue as well. ..
  6. Neuroendocrinology of Energy Balance Control
    Matthew R Hayes; Fiscal Year: 2013
    ..In addition, results may help identify potential targets for combination drug therapy to enhance the food intake and body weight suppressive effects of GLP-1- based pharmaceuticals.
  7. Trial of mesna to prevent doxorubicin-induced plasma protein oxidation and TNFa r
    Jeffrey A Moscow; Fiscal Year: 2012
    ....
  8. CD45 Pretargeted Radioimmunotherapy for AML
    Oliver W Press; Fiscal Year: 2013
    ....
  9. 1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
    Jerry D Glickson; Fiscal Year: 2012
    ..Here we are developing much more sensitive 1H NMR methods that can be used for early detection of response in all NHL patients. The same methods should be applicable to other prevalent forms of human cancer. ..
  10. Bispecific Antibody Engineering for AML RIT
    Oliver W Press; Fiscal Year: 2013
    ..We anticipate rapid translation of the results of these preclinical experiments into our clinical RIT program for AML. ..
  11. Evaluation of the in vivo effects of genes regulating Ataxin1 levels in SCA1 mice
    Qiumin Tan; Fiscal Year: 2013
    ..In the hope of eventually developing combination drug therapy, which might be more effective and less toxic, I will seek additional ATXN1-modulating pathways in Aim 2...
  12. Novel Mechanisms by which RAD18 and POLZ affect Response to Anticancer Agents
    CHRISTINE ELIZABETH CANMAN; Fiscal Year: 2012
    ....
  13. Ocular HSV-Latency, Reactivation, and Recurrence
    James M Hill; Fiscal Year: 2012
    ..The use of two receptor-based ApoE mimetic peptides that exhibit potent anti-viral and anti-inflammatory activity, and which act to suppress this gene, holds great promise as a new therapy for ocular and other HSV-related diseases. ..
  14. Combination Therapy in B-Chronic Lymphocytic Leukemia
    Neil E Kay; Fiscal Year: 2012
    ....
  15. Anaerobic shock as a novel treatment for tuberculosis
    Xilin Zhao; Fiscal Year: 2010
    ..The present program seeks to develop a novel, rapid, and highly efficient treatment of tuberculosis upon induction of self-destructive autolysis of Mycobacterium tuberculosis. ..
  16. Neural mechanism of glucagon-like-peptide-1 receptor-mediated nausea /malaise
    Matthew R Hayes; Fiscal Year: 2013
    ..In addition, results may help identify potential targets for combination drug therapy to ameliorate the malaise side effects of current FDA-approved GLP-1R ligands.
  17. Targeting malarial dihydroorotate dehydrogenase
    Pradipsinh K Rathod; Fiscal Year: 2010
    ..Despite intensive efforts to control malaria through combination drug therapy and insect control programs, malaria remains one of the largest global health problems...
  18. Ex Vivo Model for Assessing the Vaginal Disposition of PrEP Antiretrovirals
    MARC MICHAEL BAUM; Fiscal Year: 2013
    ..b>Combination drug therapy often introduces complex drug-drug interactions that can result in toxic or sub-therapeutic drug ..
  19. Proteasome Inhibition and ER Stress
    David J McConkey; Fiscal Year: 2013
    ..abstract_text> ..
  20. Retroviral replicating vector for prodrug activator gene therapy
    Douglas J Jolly; Fiscal Year: 2012
    ..It may also be applicable to brain metastases caused by other malignancies. ..
  21. Pharmacogenetics of Cyclophosphamide ADRs in
    Jeannine S McCune; Fiscal Year: 2012
    ....
  22. The Influence of Diet and Lifestyle on Patients with Advanced Colorectal Cancer
    Jeffrey A Meyerhardt; Fiscal Year: 2013
    ..abstract_text> ..
  23. Pharmacogenomics of Breast Cancer Adjuvant Chemotherapy
    Richard M Weinshilboum; Fiscal Year: 2011
    ..We propose a genome-wide association study of the 3754 women who participated in the Success A breast cancer clinical trial to identify genomic markers that will make it possible to better "individualize" breast cancer chemotherapy. ..
  24. Pharmacogenetics in children with high-risk neuroblastoma
    Jeannine S McCune; Fiscal Year: 2013
    ....
  25. Targeting c-MYC Overcomes Temsirolimus and Cisplatin Resistance of Ovarian Cancer
    PABLO ELIAS VIVAS-MEJIA; Fiscal Year: 2013
    ..This proposal is unique in the evaluation of the therapeutic potential of targeting c-MYC to overcome TEM and cisplatin resistance of ovarian cancer cells. ..
  26. Enhancing the vaccinal effect of antitumor antibodies
    Raphael A Clynes; Fiscal Year: 2013
    ....
  27. Search Algorithms for Drug Combinations: Extending Approved Cancer Therapies
    Carlo Piermarocchi; Fiscal Year: 2013
    ..b>Combination drug therapy is commonly used to enhance efficacy and overcome drug resistance in cancer, but at present the choice of ..
  28. Improving the Efficacy of Cisplatin-Based Cancer Chemotherapy
    Macus T Kuo; Fiscal Year: 2013
    ..This is mechanism-driven research that has important translational implications to improve the efficacy of Pt-based cancer chemotherapy using clinically approved Cu-lowering agents. ..
  29. Phase 1/2 of AT-101 With Lenalidomide for Tx of Chronic Lymphocytic Leukemia
    Asher A Chanan-Khan; Fiscal Year: 2012
    ..This Phase 2/3 clinical trial is proposed to determine the maximum tolerated dose (MTD), to determine the efficacy of the lenalidomide/AT-101 combination, and to test this hypothesis in CLL patients with relapsed disease. ..
  30. Infant and Toddler Brain Tumors
    James M Olson; Fiscal Year: 2013
    ..The significance of this work is that pediatric neuro-oncologists will abandon the highly toxic and ineffective therapeutic regimens that we are currently using in favor of a targeted approach that has higher efficacy and less toxicity. ..
  31. NANOTHERAPEUTIC STRATEGY FOR MULTIDRUG RESISTANT TUMORS
    Mansoor Amiji; Fiscal Year: 2009
    ..use mathematical modeling to improve the design of nanocarriers for tumor-targeted delivery of single and combination drug therapy. The results of this study would be extremely valuable in the treatment of refractory tumors using a ..
  32. Thermally targeted drug delivery by elastin biopolymers
    Ashutosh Chilkoti; Fiscal Year: 2013
    ....
  33. Enhancing bone strength using combination drug therapy
    Matthew R Allen; Fiscal Year: 2013
    ..As UTE-MRI can be utilized in humans, these data have the potential to launch a new focus area for non- invasive methods of fracture risk assessment. ..
  34. Oral Chemotherapy in AIDS-related NHL in Uganda & Kenya
    Scot Remick; Fiscal Year: 2003
    ..abstract_text> ..
  35. Diphtheria fusion protein therapy of AML
    ARTHUR FRANKEL; Fiscal Year: 2006
    ..These studies should lead to the design of pivotal phase II clinical trials to determine the role of this therapeutic in AML management. ..
  36. MECHANISMS AND MODULATION OF ETOPOSIDE--VP-16 RESISTANCE
    Jack Yalowich; Fiscal Year: 1991
    ..Results of the proposed studies will further understanding of VP-16 activity when used alone or in combination and will contribute fundamental information of gene regulatory systems and mechanisms of acquired drug resistance...
  37. HYDROXYUREA SYNERGY WITH OTHER ANTICANCER DRUGS IN VIVO
    William Vaughan; Fiscal Year: 1990
    ....
  38. COMBATING ALKYLATING AGENT RESISTANCE IN HUMAN GLIOMAS
    JOHN SILBER; Fiscal Year: 2002
    ..In an effort to define the role of 3-MAG in clinical drug resistance, enzyme levels will be correlated with response to alkylator adjuvant therapy and clinical course. ..
  39. DEVELOPMENT OF POTENTIAL NEW AGENTS AGAINST MELANOMA
    Andre Rosowsky; Fiscal Year: 1980
    ....
  40. Clinical trial of chloroquine combinations in Malawi
    CHRISTOPHER PLOWE; Fiscal Year: 2009
    b>Combination drug therapy for malaria, especially artemisinin-based combination therapy (ACT), is intended to deter resistance by rapidly eliminating malaria parasites using drugs with different mechanisms...
  41. NOVEL COMBINATION THERAPY OF NEUROBLASTOMA
    Nai Kong Cheung; Fiscal Year: 2000
    ..Because GD2 is found on a variety of human tumors, these results may have therapeutic implications for other refractory human cancers. ..
  42. RANDOMIZED CLINICAL TRIAL OF A CAPILLARY CLONING SYSTEM
    Daniel Von Hoff; Fiscal Year: 1990
    ....
  43. BIOSYNTHESIS OF PEPTIDE/POLYKETIDE DERIVED ANTIBIOTICS
    Ben Shen; Fiscal Year: 2001
    ....
  44. CLINICAL TRAILS IN PEDIATRIC RHEUMATOLOGY
    Daniel Lovell; Fiscal Year: 2004
    ..includes a prospective, randomized, actively controlled, open clinical trial to determine the efficacy of combination drug therapy to induce prolonged drug-free remission in children with severe systemic JRA (sJRA)...
  45. NOVEL TUMOR ANTIGEN FOR ANTIBODY TARGETING
    Nai Kong Cheung; Fiscal Year: 2001
    ..This information is critical for radioimmunotherapy as well as future antibody-based targeted therapies. ..
  46. MITOMYCINS UNRAVELLED
    Harold Kohn; Fiscal Year: 1999
    ..Members of both classes of compounds are undergoing clinical trials. Knowledge from these studies will contribute to our understanding of the mitomycins and serve as the basis for the design of new DNA site-specific anticancer drugs. ..
  47. PBSC SUPPORT OF HIGH-DOSE THERAPY FOR OVARIAN CANCER
    Russell Schilder; Fiscal Year: 1993
    ..Once it has been established that high-dose therapy can be safely administered, prospective randomized trials will be necessary to determine the effect upon survival...
  48. HIV, LEUKEMIA, AND OPPORTUNISTIC CANCERS
    Myron Essex; Fiscal Year: 1999
    ..The Symposium will have open enrollment and interested participants are invited to submit abstracts for oral or poster presentation. Attendance will be limited to 1,000 registrants. ..
  49. Leukemia Signatures for Risk Classification & Targeting
    Cheryl Willman; Fiscal Year: 2009
    ..We will compare expression signatures for classification and outcome prediction in adult vs. pediatric AML and refine profiles that predict response or resistance to new targeted therapies (FLT3 and farnesvl transferase inhibitors). ..
  50. Pharmacogenetics in Ovarian Cancer
    Kirsten Moysich; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  51. COMBINATION CHEMOTHERAPY FOR PANDEMIC INFLUENZA
    Robert Webster; Fiscal Year: 2005
    ....
  52. PHARMACOLOGICAL EFFECTS OF ETHER LIPID ANALOGS
    EDWARD MODEST; Fiscal Year: 1991
    ..the ability of the compounds to accelerate monocyte maturation, which may contribute to in vivo antitumor activity by increasing the number of mature tissue macrophages available for activation, will be examined...
  53. MRI Detection of Doxorubicin Induced Cardiotoxicity
    WILLIAM HUNDLEY; Fiscal Year: 2007
    ..In addition, further animal studies will be designed to identify treatment strategies for Doxorubicin induced cardiotoxicity. [unreadable] [unreadable]..
  54. Pharmacogenetics advanced colorectal cancer
    Howard McLeod; Fiscal Year: 2004
    ..These aims provide a comprehensive framework for our strategy to provide the first prospective information on the integration of pharmacogenetic information into the selection of therapy for advanced colorectal cancer. ..
  55. RATIONAL APPROACHES TO COMBINATION CHEMOTHERAPY
    ALEXANDER BLOCH; Fiscal Year: 1980
    ..Integration of the information obtained with these basic approaches should lead to a better understanding of the regulation of DNA synthesis and a more judicious use of antimetabolites both alone and in combination for clinical therapy...
  56. Targeted Prodrug Therapy of Liver Cancers
    MACUS KUO; Fiscal Year: 2005
    ....
  57. IRINOTECAN AND CYTARABINE IN ACUTE MYELOID LEUKEMIA
    Maria Baer; Fiscal Year: 2001
    ..To optimize the schedule of CPT-11 and Ara-C combination chemotherapy based on laboratory correlates of efficacy; and 3. To identify correlates of sensitivity and resistance to CPT-11 and Ara-C combination chemotherapy. ..
  58. CLINICAL TRIALS AND MENTORING IN ONCOLOGY RESEARCH
    Robert Motzer; Fiscal Year: 2003
    ..One recently joined staff at MSKCC in the Genito-urinary Section. Mentoring of clinical trials is extended beyond fellowship to junior faculty members. ..
  59. Targeted Prodrug Therapy of Liver Cancers
    John Chan; Fiscal Year: 2004
    ..This novel prodrug targeting therapy is effective, technically simple, non-invasive and cost effective, which should have enormous commercial potential. ..
  60. SYNERGISM DURING COMBINATION CANCER CHEMOTHERAPY
    PHILIP KLUBES; Fiscal Year: 1980
    ..Hopefully, this will lead to rational suggestions for the better use of combinations of anticancer drugs against human solid tumors...
  61. Development of PT523 for the treatment of lung cancer
    MAREK WOLTER; Fiscal Year: 2005
    ..c. transplants. The agent(s) that are most efficacious in inhibition of tumor growth and best tolerated in combination with PT523 will be selected. ..
  62. Optimizing Coordinated Combination Drug Therapy
    Roger Jelliffe; Fiscal Year: 2009
    A major problem in optimally coordinating combination drug therapy is the inability to quantify and minimize the highly variable relationships between dosage of the various drugs, patient adherence, serum concentrations, drug - drug ..